Clinical trials: Primary Headache Disorders
Cluster Headache
The Efficacy of L-cysteine in Prevention of Cluster Headache
The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the attacks of cluster headache.
- Trial name
- NCT02310828
- Testing
- Acetium
- Where
- 6 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Biohit Oyj
Migraine
Open-trial on the Prevention of Chronic Migraines With the CEFALY Device
The main objective of this study was to assess the safety and efficacy of the Cefaly® e-TNS device as a prophylactic treatment of chronic migraine in adult patients.
- Trial name
- NCT02342743
- Testing
- CEFALY
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Cefaly Technology
Migraine
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
- Trial name
- CONQUER (NCT03559257)
- Testing
- Galcanezumab
- Where
- 69 sites in United States, Belgium and 11 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Migraine
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
- Trial name
- NCT00384774
- Testing
- Lasmiditan
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Migraine, Acute Treatment of Migraine
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain")…
- Trial name
- NCT01430442
- Testing
- Rimegepant, Sumatriptan
- Where
- 41 sites in United States
- Volunteers
- 1,026 people
- Sponsor
- Pfizer
Migraine
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant.
- Trial name
- NCT06578585
- Testing
- Ubrogepant, Lu AG09222
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- H. Lundbeck A/S
Acute Migraine
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
- Trial name
- NCT05371652
- Testing
- Rimegepant 75mg Orally Disintegrating Tablets (ODT)
- Where
- 26 sites in China
- Volunteers
- 241 people
- Sponsor
- Pfizer
Migraine
A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese migraine patients using an autoinjector (AI) at home.
- Trial name
- NCT04355117
- Testing
- Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period.
- Trial name
- NCT01125774
- Testing
- Telcagepant
- Volunteers
- 4,548 people
- Sponsor
- Merck Sharp & Dohme LLC
Headache, Tension-Type
A Pharmacokinetic Study of an Experimental Paracetamol Formulation
This PK study is designed to show bioequivalence between the study treatments.
- Trial name
- NCT01476176
- Testing
- Experimental paracetamol, Paracetamol marketed formulation
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine, Episodic Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
- Trial name
- CHALLENGE-MIG (NCT05127486)
- Testing
- Galcanezumab, Rimegepant
- Where
- 77 sites in United States
- Volunteers
- 580 people
- Sponsor
- Eli Lilly and Company
Migraine
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
This is a multicenter, open-label, non-randomized, parallel-group, single dose study. This study will enroll up to 24 participants and will include 2 hepatic impaired participant groups and one group of control participants with…
- Trial name
- NCT03040479
- Testing
- lasmiditan 200 mg
- Where
- 3 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-2 (NCT02614196)
- Testing
- Galcanezumab
- Where
- 113 sites in United States, Argentina and 10 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Migraine, Acute Treatment of Migraine
Nerivio Efficacy by Time of Treatment Onset
This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine.
- Trial name
- NCT06976723
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 55,261 people
- Sponsor
- Theranica
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories
High Blood Pressure, Migraine Headaches
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
- Conditions
- High Blood Pressure, Migraine Headaches, Chest Pain
- Trial name
- NCT00960245
- Testing
- Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sandoz
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
- Trial name
- NCT02198339
- Testing
- BIBN 4096 BS
- Volunteers
- 126 people
- Sponsor
- Boehringer Ingelheim
Migraine
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited.
- Trial name
- NCT07487701
- Testing
- Nerivio REN device
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Theranica
Migraine Headache
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
- Trial name
- NCT01462812
- Testing
- Sumatriptan
- Where
- 15 sites in United States
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.